Does Rallies show 13F holders for PLX?

Yes. Rallies tracks hedge fund and 13F ownership data for PLX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PLX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PLX. It does not provide personalized investment advice.

PLX (Protalix BioTherapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Protalix BioTherapeutics, Inc. Common Stock (PLX) is a publicly traded Healthcare sector company. As of May 21, 2026, PLX trades at $1.94 with a market cap of $153.89M and a P/E ratio of 10.07. PLX moved +5.53% today. Year to date, PLX is +12.29%; over the trailing twelve months it is +16.86%. Its 52-week range spans $0.99 to $3.19. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces PLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PLX stock?

Hedge funds tracked by Rallies that own PLX include Sculptor Capital. The latest tracked quarter is Dec 31, 2023. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Protalix BioTherapeutics, Inc. Common Stock.

PLX Key Metrics

Key financial metrics for PLX
Metric	Value
Price	$1.94
Market Cap	$153.89M
P/E Ratio	10.07
EPS	$0.20
Dividend Yield	0.00%
52-Week High	$3.19
52-Week Low	$0.99
Volume	30
Avg Volume	0
Revenue (TTM)	$76.38M
Net Income	$15.33M
Gross Margin	69.97%

Top Hedge Funds Holding PLX

Sculptor Capital holds 37.00K shares of PLX, changed +0.00% as of Dec 31, 2023.

Latest PLX News

Protalix Extends Cash Runway into Late 2027, Completes Phase III Enrollment — May 14, 2026
Protalix Q1 Revenues Fall to $7.4M, Reaffirms $78–$83M 2026 Guidance After $25M Milestone — May 13, 2026
Protalix BioTherapeutics secures €25M after EU dosing approval, forecasts 50% growth — Mar 18, 2026
Protalix wins EU approval for monthly Elfabrio dosing, nets $25M — Mar 18, 2026
Protalix and Chiesi Secure EU Approval for 2mg/kg Every-Four-Weeks Dose, Triggering $25M Payment — Mar 9, 2026

Recent PLX Insider Trades

Bashan Dror bought 56.00K (~$101.36K) on Dec 19, 2025.
Bar-Shalev Amos sold 168 (~$314.16) on Nov 18, 2025.
Schwartz Aharon bought 129.00K (~$205.88K) on Jun 10, 2025.

PLX Analyst Consensus

1 analysts cover PLX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.

Common questions about PLX

Who owns PLX stock?: Hedge funds tracked by Rallies that own PLX include Sculptor Capital. The latest tracked quarter is Dec 31, 2023. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Protalix BioTherapeutics, Inc. Common Stock.
Does Rallies show 13F holders for PLX?: Yes. Rallies tracks hedge fund and 13F ownership data for PLX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PLX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PLX. It does not provide personalized investment advice.